Galliprant (20.4 - 34 kg)

1 x 7 pc

Tablet

Active substance

Grapiprant : 60 mg

ATC code

QM01AX92 Grapiprant

QM01AX Other antiinflammatory and antirheumatic agents, non-steroids (NSAIDs)

QM01A Antiinflammatory and antirheumatic products, non-steroids (NSAIDs)

QM01 Antiinflammatory and antirheumatic products

QM Musculo-skeletal system

Species

Dogs.

Indications

For the treatment of pain associated with mild to moderate osteoarthritis in dogs.

Dose to be administered and administration route

For oral use.

Administer this veterinary medicinal product on an empty stomach (e.g. in the morning) and at least one hour before the next meal, once daily at a target dose of 2 mg per kg body weight (bw).

Duration of treatment will depend on the response observed to treatment. As field studies were limited to 28 days, longer-term treatment should be considered carefully and regular monitoring undertaken by the veterinarian.

Since clinical signs of canine osteoarthritis wax-and-wane, intermittent treatment may be beneficial in some dogs.

The following number of tablets should be given once daily:

Body weight (kg)	20 mg tablet	60 mg tablet	100 mg tablet	Dose range (mg/kg bw)
3.6-6.8	0.5			1.5-2.7
6.9-13.6	1			1.5-2.9
13.7-20.4		0.5		1.5-2.2
20.5-34.0		1		1.8-2.9
34.1-68.0			1	1.5-2.9
68.1-100.0			2	2.0-2.9

Adverse reactions

Target species: Dogs

Very common

(>1 animal / 10 animals treated):

Vomiting

Common

(1 to 10 animals / 100 animals treated):

Loose stool, Diarrhoea

Inappetance

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Haematemesis, Haemorrhagic

diarrhoea

Pancreatitis

Elevated blood urea nitrogen (BUN), Elevated creatinine, Elevated liver enzymes, Hypoalbuminaemia¹,

Hypoproteinaemia¹

¹These signs were not associated with any clinically significant observations or events.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See section ‘Contact details’ of the package leaflet.